QIAGEN N.V. (QGEN) stock
QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$49.56−0.19 (-0.38%)
Close on Nov 18, 2026Market cap $10.75BP/E 25.5Yield 0.50%
Qiagen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $465.85M, up 376.8% from the year before. Over ten years it grew 10.0% a year on average. The highest annual figure on record is $630.08M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $465.85M | +376.8% |
| FY2024 | Dec 31, 2024 | $97.71M | -76.2% |
| FY2023 | Dec 31, 2023 | $409.94M | -22.9% |
| FY2022 | Dec 31, 2022 | $531.46M | -15.7% |
| FY2021 | Dec 31, 2021 | $630.08M | +63.1% |
| FY2020 | Dec 31, 2020 | $386.43M | – |
| FY2019 | Dec 31, 2019 | -$26.14M | -109.8% |
| FY2018 | Dec 31, 2018 | $266.58M | +73.8% |
| FY2017 | Dec 31, 2017 | $153.42M | +55.2% |
| FY2016 | Dec 31, 2016 | $98.83M | -44.9% |
| FY2015 | Dec 31, 2015 | $179.50M | +11.0% |
| FY2014 | Dec 31, 2014 | $161.69M | +155.3% |
| FY2013 | Dec 31, 2013 | $63.33M | -62.7% |
| FY2012 | Dec 31, 2012 | $169.81M | +70.5% |
| FY2011 | Dec 31, 2011 | $99.59M | -47.2% |
| FY2010 | Dec 31, 2010 | $188.54M | +4.6% |
| FY2009 | Dec 31, 2009 | $180.21M | +23.7% |
| FY2008 | Dec 31, 2008 | $145.66M | – |
See a number that looks wrong?